{"id":124016,"date":"2026-07-07T07:45:11","date_gmt":"2026-07-07T07:45:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/124016\/"},"modified":"2026-07-07T07:45:11","modified_gmt":"2026-07-07T07:45:11","slug":"novo-nordisk-buyback-support-and-hsbc-upgrade-fuel-recovery-but-overbought-signals-and-analyst-spl","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/124016\/","title":{"rendered":"Novo Nordisk: Buyback Support and HSBC Upgrade Fuel Recovery, But Overbought Signals and Analyst Spl"},"content":{"rendered":"<p>Novo Nordisk\u2019s share price has clawed back ground from March lows, driven by a massive buyback programme and a fresh analyst upgrade from HSBC. Yet the rally is unfolding against a backdrop of technical overextension and divergent analyst views, leaving the stock in a tug-of-war between structural support and competitive headwinds.<\/p>\n<p>The pharmaceutical giant closed Monday at \u20ac43.06, up 20.63% over the past 30 days and 2.66% in the last seven trading sessions. The advance has trimmed the year-to-date decline to 3.63%, though the stock remains 27.29% lower than a year ago. HSBC last week raised its price target to 300 Danish kroner from 280 kroner, a vote of confidence in the company\u2019s outlook. Not all analysts are convinced, however: one current rating carries a \u201chold\u201d recommendation with a target of just $42, roughly in line with Monday\u2019s close, citing a weak 2026 outlook and rising pricing pressure in the GLP-1 market.<\/p>\n<p>Underpinning the recovery is a steady stream of share repurchases. Under a buyback framework of up to 15 billion Danish kroner authorised in February 2026, the company has already bought back 23,009,179 B-shares since the start. The current tranche, launched on 6 May under EU Safe Harbour rules, targets up to 11.2 billion kroner in purchases by 1 February 2027. Between 29 June and 3 July alone, Novo Nordisk snapped up an additional 1 million B-shares, bringing the total held in treasury to 40,194,480 shares \u2014 exactly 0.9% of the company\u2019s total capital. The average price paid since February is around 270 kroner per share, with total spending of 6.2 billion kroner, equivalent to 41% of the overall budget.<\/p>\n<p style=\"margin: 2em 0; color: #374151; font-size: inherit; line-height: 1.6; font-style: italic;\"><a href=\"https:\/\/www.stockstoday.com\/lp\/analysis\/?trk=ST_Asset_Analysis_Middle_RSS-Feed&amp;isin=DK0062498333&amp;aktienname=Novo+Nordisk&amp;adref=Blog_Ad-Hoc-News%3AEx-Article-ID_187554%3AISIN_DK0062498333%3AAsset_Novo+Nordisk%3ASource_Ad-Hoc-News&amp;source=RSS-Ad-Hoc-News&amp;Language=English\" rel=\"noopener nofollow\" style=\"color: #337ab7 !important; font-weight: bold; text-decoration: underline;\" target=\"_blank\">Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n<p>Technically, the stock has rallied above key moving averages. It now trades 10.75% above the 50-day simple moving average of \u20ac38.88 and 5.64% above the 200-day line of \u20ac40.76. The 14-day relative strength index stands at 67.4, edging toward overbought territory, while the 30-day annualised volatility clocks in at 31.47%. The primary source noted an RSI of nearly 69, reinforcing the message that the recent pace of gains may be unsustainable in the near term.<\/p>\n<p>The buyback\u2019s structural impact is clear: a shrinking share count automatically boosts earnings per share and provides a consistent buyer in the market. Yet the stock still sits 29.64% below its 12-month high of \u20ac61.20 from last July, despite a 42.35% rebound from the March trough of \u20ac30.25. That gap highlights the magnitude of the earlier sell-off, triggered by intensifying competition in the obesity-drug space and uncertainty around Novo Nordisk\u2019s growth trajectory.<\/p>\n<p>The half-year results, due in the coming weeks, will serve as the next major catalyst. They will test whether the current rally reflects a genuine improvement in fundamentals or merely a technical bounce fuelled by buyback demand and short-covering. Until then, the stock remains a study in contrasts: a buyback machine supporting the price from below, while analyst scepticism and overbought signals cap the upside.<\/p>\n<p align=\"right\" style=\"font-size:10px;margin:0;\">Ad<\/p>\n<p style=\"margin-bottom: 1em;\">Novo Nordisk Stock: New Analysis &#8211; 7 July<\/p>\n<p style=\"margin-bottom: 1em;\">Fresh Novo Nordisk information released. What&#8217;s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n<p style=\"margin-bottom: 1em;\"><a href=\"https:\/\/www.stockstoday.com\/lp\/analysis\/?trk=ST_Asset_Analysis_Bottom_RSS-Feed&amp;isin=DK0062498333&amp;aktienname=Novo+Nordisk&amp;adref=Blog_Ad-Hoc-News%3AEx-Article-ID_187554%3AISIN_DK0062498333%3AAsset_Novo+Nordisk%3ASource_Ad-Hoc-News&amp;source=RSS-Ad-Hoc-News&amp;Language=English\" rel=\"noopener nofollow\" style=\"color: #337ab7 !important; font-weight: bold; text-decoration: underline;\" target=\"_blank\">Read our updated Novo Nordisk analysis&#8230;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk\u2019s share price has clawed back ground from March lows, driven by a massive buyback programme and&hellip;\n","protected":false},"author":2,"featured_media":124017,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[8858,11307,21752,1899,5691,3845,272,48458,19366,1865,13856],"class_list":["post-124016","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-but","tag-buyback","tag-fuel","tag-hsbc","tag-nordisk","tag-novo","tag-novo-nordisk","tag-overbought","tag-recovery","tag-support","tag-upgrade"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116877585694904494","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/124016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=124016"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/124016\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/124017"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=124016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=124016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=124016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}